The table below from the 10-Q (p. 20) shows the indication for which each of BioMarin's products is approved: BioMarin's latest 10-K (pps. 11-12 ) (the "10-K") includes the following explanatory ...
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday. Other research analysts also ...
State of Alaska Department of Revenue cut its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 25.6% during the 4th quarter, according to the company in its most ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is expanding its portfolio through the development of new therapies and the exploration of novel indications for existing products. The company recently ...
BioMarin Pharmaceutical (BMRN) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Studies have ...
BioMarin Pharmaceutical (BMRN) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Research shows ...
Wedbush analyst Yun Zhong maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of $94.00. Discover outperforming stocks and invest smarter ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.